Odefsey

RPV/FTC/TAF rilpivirine/emtricitabine/tenofovir alafenamide

Recommended initial regimen in certain clinical situations
Single-Tablet Regimen

Standard Dose

One tablet once daily, with a standard meal. For people taking HIV therapy for the first time (treatment-naïve) or people with suppressed viral load on a stable HIV regimen for at least six months who have no known resistance to the components of the regimen: rilpivirine, emtricitabine, or TAF. See below. Tablet contains 25 mg of the NNRTI rilpivirine plus 200 mg emtricitabine and 25 mg tenofovir alafenamide (TAF).

For adults and children 12 years of age and older weighing at least 77 pounds (35 kg) and having a CrCl of at least 30 mL/min, or people with a CrCl less than 15 mL/min who are receiving dialysis.

Must be taken with food that you chew—not just nutritional drinks, protein shakes, or a light snack. Taking rilpivirine without enough food could result in up to a 40% decrease in drug absorption and may lead to resistance.

According to DHHS guidelines, people taking HIV treatment for the first time should have an HIV RNA (viral load) of less than 100,000 copies/mL and CD4 T cell count must be above 200 cells/mm3 before starting Odefsey due to higher rates of virologic failure in these patients. The CD4 requirement, however, is no longer on the drug label.

Take missed dose as soon as possible, unless it is closer to the time of your next dose. Do not double up on your next dose.
  • See the individual drugs contained in Odefsey: Edurant and Descovy (coformulation of Emtriva and TAF).
  • See package insert for more complete information on potential side effects and interactions.

Manufacturer

Gilead Sciences, Inc.
gilead.com; odefsey.com
(800) GILEAD-5 (445-3235)

Janssen Therapeutics
janssentherapeutics.com
(800) JANSSEN (526-7736)

AWP

$3,706.28/month

Potential Side Effects and Toxicity

Potential Drug Interactions

More Information

Doctor Comments

Activist Comments